Delaporte E - Search Results

1

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group. Ciaffi L, et al. Among authors: delaporte e. Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28. Lancet HIV. 2017. PMID: 28566227 Clinical Trial.

2

Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.

Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, Delaporte E. Vergne L, et al. Among authors: delaporte e. J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):165-8. doi: 10.1097/00042560-200202010-00009. J Acquir Immune Defic Syndr. 2002. PMID: 11832686

3

Identification of a new circulating recombinant form of HIV type 1, CRF11-cpx, involving subtypes A, G, J, and CRF01-AE, in Central Africa.

Montavon C, Vergne L, Bourgeois A, Mpoudi-Ngole E, Malonga-Mouellet G, Butel C, Toure-Kane C, Delaporte E, Peeters M. Montavon C, et al. Among authors: delaporte e. AIDS Res Hum Retroviruses. 2002 Feb 10;18(3):231-6. doi: 10.1089/08892220252781301. AIDS Res Hum Retroviruses. 2002. PMID: 11839159

4

CRF06-cpx: a new circulating recombinant form of HIV-1 in West Africa involving subtypes A, G, K, and J.

Montavon C, Toure-Kane C, Nkengasong JN, Vergne L, Hertogs K, Mboup S, Delaporte E, Peeters M. Montavon C, et al. Among authors: delaporte e. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):522-30. doi: 10.1097/00126334-200204150-00014. J Acquir Immune Defic Syndr. 2002. PMID: 11981370

5

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study.

Laurent C, Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E. Laurent C, et al. Among authors: delaporte e. AIDS. 2002 Jul 5;16(10):1363-70. doi: 10.1097/00002030-200207050-00008. AIDS. 2002. PMID: 12131213 Clinical Trial.

6

Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny.

Courgnaud V, Salemi M, Pourrut X, Mpoudi-Ngole E, Abela B, Auzel P, Bibollet-Ruche F, Hahn B, Vandamme AM, Delaporte E, Peeters M. Courgnaud V, et al. Among authors: delaporte e. J Virol. 2002 Aug;76(16):8298-309. doi: 10.1128/jvi.76.16.8298-8309.2002. J Virol. 2002. PMID: 12134035 Free PMC article.

7

No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.

Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, Gueye M, Liégeois F, Kane CT, Butel C, Mbuagbaw J, Zekeng L, Mboup S, Mpoudi-Ngolé E, Peeters M, Delaporte E. Laurent C, et al. Among authors: delaporte e. J Infect Dis. 2002 Aug 15;186(4):486-92. doi: 10.1086/341833. Epub 2002 Jul 19. J Infect Dis. 2002. PMID: 12195375

8

Partial molecular characterization of two simian immunodeficiency viruses (SIV) from African colobids: SIVwrc from Western red colobus (Piliocolobus badius) and SIVolc from olive colobus (Procolobus verus).

Courgnaud V, Formenty P, Akoua-Koffi C, Noe R, Boesch C, Delaporte E, Peeters M. Courgnaud V, et al. Among authors: delaporte e. J Virol. 2003 Jan;77(1):744-8. doi: 10.1128/jvi.77.1.744-748.2003. J Virol. 2003. PMID: 12477880 Free PMC article.

9

Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal.

Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, Kane CT, Delaporte E, Sow PS, Faye MA, Gueye M, Peytavin G, Dalban C, Girard PM, Ndoye I; Imea 011/ANRS 12-04 Study Group. Landman R, et al. Among authors: delaporte e. AIDS. 2003 May 2;17(7):1017-22. doi: 10.1097/00002030-200305020-00010. AIDS. 2003. PMID: 12700451 Clinical Trial.

10

High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid.

Vergne L, Paraskevis D, Vandamme AM, Delaporte E, Peeters M. Vergne L, et al. Among authors: delaporte e. AIDS. 2003 May 2;17(7):1105-7. doi: 10.1097/00002030-200305020-00028. AIDS. 2003. PMID: 12700469 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

743 results

Search Page

Filters